Clin Cancer Res: Treatment-free survival after immune + targeted therapy in advanced renal cell carcinoma

Compared with targeted therapy, immune checkpoint inhibitors (ICI) produce unique anti-tumor responses and toxicity patterns
.

Patients who discontinue immunotherapy may be able to enjoy a period of disease control that does not require continuous anti-cancer treatment, but the toxicity of immunotherapy may persist

immunity

This study outlines the treatment-free survival (TFS) of patients with advanced renal cell carcinoma undergoing immunotherapy with or without toxicity
.

The study data comes from the Phase 3 CheckMate 214 trial.
In this trial, a total of 1,096 newly-treated advanced renal cell carcinoma (aRCC) patients received nivolumab in combination with ipilimumab (n=550) or sunitinib ( n=546) Treatment
.

Definition of treatment-free survival: the time from the end of treatment to subsequent systemic treatment or death

Sunitinib

TFS in low-risk patients in the two treatment groups

TFS in low-risk patients in the two treatment groups

At the 42nd month after randomization, 52% and 39% of the low- and medium-risk patients in the nivolumab + ipilimumab group and the sunitinib group were still alive; 18% and 5% of the patients, respectively No additional treatment was given
.

Among patients at favorable risk, 70% and 73% of the patients in the nivolumab+ipilimumab group and the sunitinib group were still alive; 20% and 9% of the patients were not treated with additional treatment, respectively

52% and 39% of low- and medium-risk patients in the nivolumab+ipilimumab group and sunitinib group, respectively, were still alive; 18% and 5% of the patients did not receive additional treatment, respectively

TFS of favorable risk patients in the two treatment groups

TFS of favorable risk patients in the two treatment groups

The average EFS of low-risk patients in the nivolumab + ipilimumab group was twice that of the sunitinib group (6.
9 vs 3.
1 months); the average EFS of favorable-risk patients in the nivolumab + ipilimumab group It was three times that of the sunitinib group (11.
0 vs 3.
7 months)
.

In the two treatment groups, the average TFS with treatment-related adverse reactions of grade 3 and above accounted for only a small part of the time: nivolumab + ipilimumab group vs sunitinib group: 0.

The average EFS of low-risk patients in the nivolumab + ipilimumab group was twice that of the sunitinib group (6.

Regardless of the patient's risk, compared with the sunitinib group, patients with advanced renal cell carcinoma treated with nivolumab combined with ipilimumab have significantly longer survival times without additional treatment without immune side effects

Original source:

Meredith M.

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial in this message